[
  {
    "ts": null,
    "headline": "US CDC expects COVID and RSV levels to increase in coming weeks",
    "summary": "The U.S. Centers for Disease Control and Prevention said on Wednesday it expects to see an increase in levels of COVID-19 and respiratory syncytial virus in the country in the coming weeks, as they...",
    "url": "https://finnhub.io/api/news?id=b8a7583a60adbc585cbf1d0bf05d138794d913056a069e47cea6a4b0c10779cc",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732112566,
      "headline": "US CDC expects COVID and RSV levels to increase in coming weeks",
      "id": 131516617,
      "image": "",
      "related": "MRNA",
      "source": "Finnhub",
      "summary": "The U.S. Centers for Disease Control and Prevention said on Wednesday it expects to see an increase in levels of COVID-19 and respiratory syncytial virus in the country in the coming weeks, as they...",
      "url": "https://finnhub.io/api/news?id=b8a7583a60adbc585cbf1d0bf05d138794d913056a069e47cea6a4b0c10779cc"
    }
  },
  {
    "ts": null,
    "headline": "Franklin Biotechnology Discovery Fund Q3 2024 Commentary",
    "summary": "Following underperformance in Q2 2024, the Franklin Biotechnology Discovery Fund returned to strength in Q3 2024. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=430107a11e6198edece261d730125acfb012b52d917ba59e2778e4e7a632b2ca",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732099500,
      "headline": "Franklin Biotechnology Discovery Fund Q3 2024 Commentary",
      "id": 131504006,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/169999232/image_169999232.jpg?io=getty-c-w1536",
      "related": "MRNA",
      "source": "SeekingAlpha",
      "summary": "Following underperformance in Q2 2024, the Franklin Biotechnology Discovery Fund returned to strength in Q3 2024. Click here to read the full commentary.",
      "url": "https://finnhub.io/api/news?id=430107a11e6198edece261d730125acfb012b52d917ba59e2778e4e7a632b2ca"
    }
  },
  {
    "ts": null,
    "headline": "Moderna initiated with a Hold at Berenberg",
    "summary": "Berenberg analyst Harry Gillis initiated coverage of Moderna (MRNA) with a Hold rating and $42 price target. The firm says mRNA will revolutionize the treatment of multiple diseases. However, the analyst prefers BioNTech (BNTX) for exposure relative to Moderna. Moderna is quickly spending its COVID cash and will not meet 2028 breakeven guidance, despite recent downgrades, the analyst tells investors in a research note. Berenberg says the company is more vulnerable to commercial pressure due to i",
    "url": "https://finnhub.io/api/news?id=4152dfed075b604b3353666f58fe698a29b1a06e6744ec5f0845623e8265b525",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732096845,
      "headline": "Moderna initiated with a Hold at Berenberg",
      "id": 131498402,
      "image": "https://media.zenfs.com/en/tipranks_452/100c3fef7d854fea083938dbb81d9e1c",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Berenberg analyst Harry Gillis initiated coverage of Moderna (MRNA) with a Hold rating and $42 price target. The firm says mRNA will revolutionize the treatment of multiple diseases. However, the analyst prefers BioNTech (BNTX) for exposure relative to Moderna. Moderna is quickly spending its COVID cash and will not meet 2028 breakeven guidance, despite recent downgrades, the analyst tells investors in a research note. Berenberg says the company is more vulnerable to commercial pressure due to i",
      "url": "https://finnhub.io/api/news?id=4152dfed075b604b3353666f58fe698a29b1a06e6744ec5f0845623e8265b525"
    }
  }
]